Better survival rates, a marked reduction in tumor growth and DOX-mediated general toxicity, neurotoxicity and cardiotoxicity, increase in serum levels of TNF-α, IFN-γ, CCL4 and CCL17; in in vitro tests improving internalization and nuclear retention of DOX in cancer cells along with 4× increase in DOX-mediated cytotoxicity, overcoming multi-drug resistance. The gene discussed is CCL17; the disease is cancer.